Literature DB >> 21945964

Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets.

Koert J Stittelaar1, Edwin J B Veldhuis Kroeze, Larisa Rudenko, Rajeev Dhere, Sit Thirapakpoomanunt, Marie Paule Kieny, Albert D M E Osterhaus.   

Abstract

The advent of the H1N1 influenza pandemic (pH1N1) in 2009 triggered the rapid production of pandemic influenza vaccines, since seasonal influenza vaccines were expected and demonstrated not to provide significant cross-protection against the newly emerged pandemic virus. To increase vaccine production capacity and further evaluate the effectiveness of different candidate pandemic influenza vaccines, the World Health Organization stimulated the evaluation of different vaccination concepts including the use of live attenuated influenza vaccines (LAIVs). Therefore, we have immunized ferrets intranasally with a single dose of pH1N1-LAIV from different manufacturers. They all induced adequate serum HI antibody titers in the ferrets and protected them against intratracheal wild-type pH1N1 virus challenge: pH1N1 virus replication in the upper respiratory tract and lungs was reduced and no disease signs or severe broncho-interstitial pneumonia were observed in any of the vaccinated ferrets. These data together with the relatively efficient production process emphasize the potential of the LAIV concept for pandemic preparedness. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21945964     DOI: 10.1016/j.vaccine.2011.09.049

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Effectiveness of an Indian-made attenuated influenza A(H1N1)pdm 2009 vaccine: a case control study.

Authors:  Prasad S Kulkarni; Sharad Agarkhedkar; Sanjay Lalwani; Ashish R Bavdekar; Sameer Jog; Sidram K Raut; Varsha Parulekar; Shalaka S Agarkhedkar; Sonali Palkar; Somnath Mangrule
Journal:  Hum Vaccin Immunother       Date:  2014-01-09       Impact factor: 3.452

2.  Reassortment of high-yield influenza viruses in vero cells and safety assessment as candidate vaccine strains.

Authors:  Jian Zhou; Fan Yang; Jinghui Yang; Lei Ma; Yina Cun; Shaohui Song; Guoyang Liao
Journal:  Hum Vaccin Immunother       Date:  2016-09-20       Impact factor: 3.452

3.  Intranasal H5N1 vaccines, adjuvanted with chitosan derivatives, protect ferrets against highly pathogenic influenza intranasal and intratracheal challenge.

Authors:  Alex J Mann; Nicolas Noulin; Andrew Catchpole; Koert J Stittelaar; Leon de Waal; Edwin J B Veldhuis Kroeze; Michael Hinchcliffe; Alan Smith; Emanuele Montomoli; Simona Piccirella; Albert D M E Osterhaus; Alastair Knight; John S Oxford; Giulia Lapini; Rebecca Cox; Rob Lambkin-Williams
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

4.  Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories.

Authors:  Larisa Rudenko; Leena Yeolekar; Irina Kiseleva; Irina Isakova-Sivak
Journal:  Vaccine       Date:  2016-09-01       Impact factor: 3.641

5.  Impact of Pre-Existing Immunity to Influenza on Live-Attenuated Influenza Vaccine (LAIV) Immunogenicity.

Authors:  Sreeja Roy; Clare M Williams; Danushka K Wijesundara; Yoichi Furuya
Journal:  Vaccines (Basel)       Date:  2020-11-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.